STOCK TITAN

Armistice Capital reports 9.99% stake in Ekso Bionics (EKSO) amendment

Filing Impact
(Neutral)
Filing Sentiment
(Neutral)
Form Type
SCHEDULE 13G/A

Rhea-AI Filing Summary

Ekso Bionics Holdings, Inc. ownership update: Armistice Capital, LLC and Steven Boyd report beneficial ownership of 291,146 shares of common stock, representing 9.99% of the class as of 12/31/2025. The filing is an Amendment No. 4 to a Schedule 13G/A and states shared voting and dispositive power over these shares.

The disclosure explains Armistice Capital acts as investment manager to the Armistice Capital Master Fund Ltd., the direct holder; Mr. Boyd is the managing member of Armistice Capital. The Master Fund is identified as having the right to receive dividends or sale proceeds.

Positive

  • None.

Negative

  • None.





Check the appropriate box to designate the rule pursuant to which this Schedule is filed:
Rule 13d-1(b)
Rule 13d-1(c)
Rule 13d-1(d)






SCHEDULE 13G





SCHEDULE 13G





SCHEDULE 13G



Armistice Capital, LLC
Signature:/s/ Steven Boyd
Name/Title:Steven Boyd - Managing Member
Date:02/17/2026
Steven Boyd
Signature:/s/ Steven Boyd
Name/Title:Steven Boyd
Date:02/17/2026
Exhibit Information

JOINT FILING STATEMENT PURSUANT TO RULE 13d-1(k) The undersigned acknowledge and agree that the foregoing statement on Schedule 13G/A, is filed on behalf of each of the undersigned and that all subsequent amendments to this statement on Schedule 13G/A, shall be filed on behalf of each of the undersigned without the necessity of filing additional joint acquisition statements. The undersigned acknowledge that each shall be responsible for the timely filing of such amendments, and for the completeness and accuracy of the information concerning him or it contained therein, but shall not be responsible for the completeness and accuracy of the information concerning the others, except to the extent that he or it knows or has reason to believe that such information is inaccurate. Dated: February 17, 2026 Armistice Capital, LLC By: /s/ Steven Boyd Steven Boyd - Managing Member Steven Boyd By: /s/ Steven Boyd

FAQ

What stake does Armistice Capital report in EKSO?

Armistice Capital reports beneficial ownership of 291,146 shares, equal to 9.99% of Ekso Bionics' common stock as of 12/31/2025. The shares are held directly by Armistice Capital Master Fund Ltd., for which Armistice Capital is the investment manager.

Who is Steven Boyd in the EKSO Schedule 13G/A filing?

Steven Boyd is disclosed as the managing member of Armistice Capital, LLC and a reporting person on the Schedule 13G/A. He is listed with shared voting and shared dispositive power over 291,146 shares in the filing dated 02/17/2026.

Does the filing say Armistice receives dividends or sale proceeds for EKSO shares?

Yes. The filing states the Armistice Capital Master Fund Ltd. has the right to receive dividends and proceeds from sale of the reported securities. The Master Fund is the direct holder and is an investment advisory client of Armistice Capital.

What voting and disposition powers are reported for the 291,146 EKSO shares?

The Schedule 13G/A reports 0 shares with sole voting or sole dispositive power and 291,146 shares with shared voting power and shared dispositive power, as disclosed in Item 4 of the amendment.

When was this Schedule 13G/A amendment signed and filed?

The amendment bears signatures by Steven Boyd and is dated 02/17/2026. The ownership snapshot in the filing is tied to the record date 12/31/2025 for the reported percentage calculation.
Ekso Bionics

NASDAQ:EKSO

EKSO Rankings

EKSO Latest News

EKSO Latest SEC Filings

EKSO Stock Data

35.17M
2.60M
Medical Instruments & Supplies
General Industrial Machinery & Equipment, Nec
Link
United States
SAN RAFAEL